Summary
This filing is an amendment (Amendment No. 1) to Alnylam Pharmaceuticals, Inc.'s previously filed Quarterly Report on Form 10-Q for the period ended March 31, 2014. The amendment's sole purpose is to include the Fifth Amendment to Lease, dated March 27, 2014, as an exhibit (Exhibit 10.5). This lease amendment was inadvertently omitted from the original filing. The company states that the material terms of this lease amendment were already disclosed in a prior Form 8-K filing on April 2, 2014. Investors should note that this amendment does not alter any other financial or operational disclosures made in the original Form 10-Q filing. The amendment is effective as of the original filing date and does not incorporate any information or events that have occurred since then. Therefore, for a comprehensive understanding of Alnylam's financial performance and operational status as of March 31, 2014, investors should refer to the original Form 10-Q filing.
Financial Highlights
37 data points| R&D Expenses | $43.76M |
| Operating Expenses | $277.34M |
| Operating Income | -$269.06M |
| Net Income | -$250.94M |
| EPS (Basic) | $-3.70 |
| Shares Outstanding (Basic) | 67.79M |
Key Highlights
- 1Amendment No. 1 to the Form 10-Q for the period ended March 31, 2014.
- 2The amendment's only purpose is to file Exhibit 10.5: the Fifth Amendment to Lease.
- 3The lease amendment was dated March 27, 2014, and is with ARE-MA Region No. 28, LLC.
- 4The material terms of the lease amendment were previously disclosed in a Form 8-K filed on April 2, 2014.
- 5This amendment does not change any other part of the original Form 10-Q filing.
- 6The amendment speaks as of the original filing date (May 9, 2014) and does not reflect subsequent events.